Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2018-03-15 Share Issue/Capital Cha…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document title is "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French regulatory articles (L. 233-8 II du code de commerce and article 223-16 du règlement général de l'Autorité des marchés financiers - AMF). The content provides a table detailing the number of shares and voting rights as of a specific date (28/02/2018). This type of mandatory disclosure regarding share capital structure and voting rights changes, often triggered by crossing thresholds or required periodically, fits best under notifications related to share capital changes or major shareholding notifications. Since it is a direct announcement of the current share count and voting rights, it is most closely related to 'Share Issue/Capital Change' (SHA) or 'Major Shareholding Notification' (MRQ). Given the context of reporting the total number of shares and voting rights, which is a fundamental aspect of capital structure reporting required by regulators, SHA is the most appropriate fit, as it details the current state of the capital base. It is not a general regulatory filing (RNS) because it is highly specific, nor is it a dividend notice (DIV) or director dealing (DIRS).
2018-03-15 French
ABIVAX Eventplan
Regulatory Filings Classification · 1% confidence The document is a short news release dated March 12, 2018, titled "ABIVAX Eventplan". It primarily announces the schedule of upcoming investor events and explicitly states that the company will publish its financial results for the fiscal year 2017 on March 16, 2018. Since the document itself is an announcement about the *timing* of a future financial results release, and it is very short (under 5,000 characters), it fits the definition of a Report Publication Announcement (RPA). It is not the actual Earnings Release (ER) or the full Annual Report (10-K).
2018-03-12 German
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a press release dated March 12, 2018, announcing upcoming events for ABIVAX. The key content lists future dates for investor conferences (BIO-Europe Spring, BIO Asia, H.C. Wainwright) and explicitly states when financial results will be announced ('16 mars 2018 : résultats financiers annuels pour l'exercice 2017'). Since this document is an announcement *about* future events, including the release of financial results, and is not the financial results themselves (which would likely be an ER or IR), it fits best as a general announcement regarding corporate activities and investor relations. Given the options, it is a general announcement that doesn't fit the specific categories like DIV, DIRS, or CT. It is not a formal regulatory filing like a 10-K or IR. It is closest to a Report Publication Announcement (RPA) because it announces the publication of financial results, but it also covers general investor events. However, RPA is specifically for announcing the *publication* of a report. Since this is a forward-looking schedule of events including investor presentations and earnings dates, it functions as a general corporate update. Given the available codes, and since it is a short press release detailing future corporate activities and investor engagement, it is best classified as a Regulatory Filing (RNS) as a general catch-all for non-standard announcements, or potentially an Investor Presentation (IP) if the focus was on strategy, but here the focus is on scheduling. Given the structure, it is a general corporate communication. I will use RNS as the fallback for a general corporate event schedule announcement that doesn't fit the more specific categories like ER (which would contain the actual results) or IP (which would be the presentation slides/content). The document length is short (2925 chars), supporting the idea that it is an announcement rather than a full report.
2018-03-12 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is a short press release dated March 12, 2018, announcing upcoming events, including the date for the 'Full Year 2017 Financial Results' announcement (March 16, 2018) and participation in investor conferences. Since the document itself is not the financial results report (10-K or IR) but rather an announcement about when reports/events will occur, it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that it specifically announces the publication date of financial results and participation in investor events, RPA is a strong candidate, but RNS is the broader category for general announcements not covered elsewhere. However, since it is primarily an announcement about future corporate events and the release of results, and it is very short, it aligns best with RPA, which covers announcements regarding the timing or release of reports. If RPA is not strictly about the report itself but the announcement of its release, this fits. If we consider the primary purpose is to inform about upcoming investor engagement and result dates, RPA is the most specific fit among the announcement types.
2018-03-12 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document title is "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French regulatory articles (L. 233-8 II du code de commerce and article 223-16 du règlement général de l'Autorité des marchés financiers - AMF). This type of mandatory periodic disclosure, detailing the total share count and voting rights, is a specific regulatory filing requirement in France, often related to capital structure changes or mandatory updates. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). It most closely aligns with a mandatory regulatory disclosure concerning share capital, which fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Share Capital Disclosure' outside of general share change announcements (SHA) or insider dealing (DIRS). Since it is a formal, mandated disclosure of share structure data, RNS is the most appropriate general regulatory filing code.
2018-02-26 French
ABIVAX ernennt Dr. Carol L. Brosgart, M.D., zum Mitglied des Aufsichtsrats
Board/Management Information Classification · 1% confidence The document is a press release dated January 29, 2018, announcing that ABIVAX appointed Dr. Carol L. Brosgart to its Supervisory Board ('Aufsichtsrat'). This announcement details a change in the company's senior governance structure (Board of Directors/Supervisory Board). This directly corresponds to the definition of 'Board/Management Information' (MANG). It is not an Annual Report (10-K), an Earnings Release (ER), or a general regulatory filing (RNS), as it concerns a specific personnel change.
2018-01-29 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.